A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2016
At a glance
- Drugs TBA 354 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 11 Mar 2016 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 16 Dec 2015 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.
- 19 Nov 2015 New trial record